A recent report published by Infinium Global Research on gastroparesis treatment market provides in-depth analysis of segments and sub-segments in the global as well as regional gastroparesis treatment market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional gastroparesis treatment market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global gastroparesis treatment market.
Gastroparesis, known as delayed gastric emptying, arises from damage to the vagus nerve and abnormal stomach and intestinal muscle function, with diabetes frequently as the primary trigger due to nerve and vascular damage from high blood glucose levels. Gastroparesis Treatment aims to alleviate symptoms and improve nutrition. Medications like Metoclopramide (Reglan), Erythromycin, and Domperidone help stimulate stomach emptiness and alleviate nausea and vomiting. In certain cases, physicians recommend Jejunostomy tube feeding to provide essential nutrients and calories, offering extended nutritional support over oral or nasal tube feeding. Parenteral nutrition, delivering nutrients directly into the bloodstream, is an alternative to Jejunostomy tubes and aids during difficult gastroparesis periods. Furthermore, a gastric neurostimulator, surgically implanted, eases nausea and vomiting by emitting mild electrical pulses, especially beneficial for gastroparesis linked to vagus nerve damage. For some patients, pyloroplasty, a procedure widening and relaxing the pyloric valve, accelerates stomach emptying, providing relief from gastroparesis symptoms.
Gastroparesis most commonly results from diabetes; wherein high blood glucose levels cause nerve chemical alterations and harm to blood vessels supplying nerves with oxygen and nutrients. In addition to diabetes, there is a condition known as Idiopathic Gastroparesis (IG). IG is caused due to several factors such as nerve damage, muscle problems, or other medical conditions, such as scleroderma, amyloidosis, and lupus. IG is a persistent ailment affecting stomach muscle movement-controlling nerves, thus there is a prerequisite need for effective gastroparesis treatment. This treatment encompasses dietary adjustments, insulin, oral medications, and, in severe cases, the use of feeding tubes and parenteral nutrition to enhance stomach emptying and regain control of blood glucose levels. As a result, the rising prevalence of diabetes and idiopathic gastroparesis in the population is driving the expansion of the gastroparesis treatment market. Moreover, the elderly population's susceptibility to gastroparesis is heightened by factors like inefficient oral medication absorption, impaired appetite regulation, and post-meal blood sugar fluctuations. Consequently, the increasing elderly demographic grappling with gastrointestinal problems is fueling the demand for gastroparesis treatments. However, side effects of gastroparesis drugs include fatigue, nausea, vomiting, sleepiness, depression, anxiety, and problems with physical movement such as abdominal cramps. Therefore, the occurrence of side effects during treatment may restrict the growth potential of the gastroparesis treatment market. Although, personalized treatment approaches have the potential to mitigate the impact of side effects, making treatments more tolerable for patients. Therefore, embracing personalized treatment approaches in the field of gastroparesis creates an opportunity for companies to customize more effective therapies.
North America boasts the largest market share in the gastroparesis treatment market for several key reasons. The region's advanced healthcare infrastructure and robust research and development initiatives foster innovation in treatment options. Furthermore, the region's well-developed reimbursement systems and insurance coverage enhance patient access to treatment, increasing market demand. Additionally, a high prevalence of gastroparesis cases in North America, often associated with conditions like diabetes and post-surgical complications, drives the demand for effective therapies. The growing aging population prone to gastroparesis and an increasing focus on healthcare technologies contribute to North America's dominant position in the Gastroparesis treatment market, as it continues to lead in terms of market size and influence. Asia Pacific's rapid urbanization and economic growth have made it the fastest-growing market for Gastroparesis treatment. This trend is exemplified by real-world cases, such as the increased prevalence of gastroparesis in India due to shifting dietary habits, with 77 million adults aged 18 and above dealing with diabetes-related gastroparesis. Consequently, there is a rising demand for Gastroparesis treatment in the Asia Pacific region. Additionally, pharmaceutical companies are expanding their presence in Asia Pacific, offering innovative treatments.
|Market Size in 2022||USD 8.20 Billion|
|Market Size by 2030||USD 11.09 Billion|
|Growth Rate from 2023 to 2030||CAGR of 3.30%|
|Largest Market||North America|
|No. of Pages||300|
|Market Segmentation||By Type, By Drug Class, By Treatment, and By Distribution Channel|
|Regional Scope||North America, Europe, Asia Pacific, and RoW|
The report on global gastroparesis treatment market covers segments such as type, drug class, treatment, and distribution channel. On the basis of type, the sub-markets include diabetic, idiopathic, post-surgical, and others. On the basis of drug class, the sub-markets include prokinetic drugs, antiemetics, botulinum toxin injection, antidepressants, and others. On the basis of treatment, the sub-markets include jejunostomy, gastric electric stimulation, parenteral nutrition, diabetic gastroparesis, post-operative gastroparesis, and others. On the basis of distribution channel, the sub-markets include retail pharmacies, hospital pharmacies, and others.
The report provides profiles of the companies in the market such as Medtronic, Neurogastrx, Inc., Endologic, Takeda Pharmaceutical Company Limited, Theravance Biopharma, EVOKE PHARMA, Cedars-Sinai, GSK plc, CinDome Pharma, Inc., and Processa Pharmaceuticals, Inc..
The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the gastroparesis treatment market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.
Please Choose One of them.